Items where authors include "Szlosarek, P."

Article

Fennell, D.A. orcid.org/0000-0001-7373-1312, Hill, K. orcid.org/0000-0001-5289-4454, Zhang, M. et al. (37 more authors) (2025) Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial. Nature Communications, 16 (1). 6688. ISSN 2041-1723

Fennell, D.A., Griffiths, G., Ottensmeier, C. et al. (4 more authors) (2022) CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? – Authors' reply. The Lancet Oncology, 23 (1). e14-e15. ISSN 1470-2045

Fennell, D.A., Ewings, S., Ottensmeier, C. et al. (36 more authors) (2021) Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. The Lancet Oncology, 22 (11). pp. 1530-1540. ISSN 1470-2045

Fennell, D.A., Kirkpatrick, E., Cozens, K. et al. (13 more authors) (2018) CONFIRM: a double-blind, placebo controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. TRIALS, 19. 233. ISSN 1745-6215

Proceedings Paper

Hanna, G., Griffiths, G., Kirkpatrick, E.V. et al. (11 more authors) (2018) CONFIRM: a phase III randomised trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma. In: Lung Cancer. 16th Annual British Thoracic Oncology Group Conference 2018, 24-26 Jan 2018, Dublin. Elsevier , S84-S84.